Last reviewed · How we verify
FILGRASTIM
FILGRASTIM is a Leukocyte Growth Factor [EPC] drug. It is currently FDA-approved (first approved 1991).
G-CSF stimulates neutrophil production and function by binding to specific receptors on hematopoietic cells.
Filgrastim is a protein that acts as a granulocyte colony-stimulating factor receptor agonist, belonging to the agonist class of drugs. It is used to treat various conditions, including neuroblastoma, acute leukemia, leukemia, lymphoma, and oral complications, as indicated by clinical trials.
At a glance
| Generic name | FILGRASTIM |
|---|---|
| Drug class | Leukocyte Growth Factor [EPC] |
| Target | Specific cell surface receptors on hematopoietic cells |
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 1991 |
Mechanism of action
G-CSF is a glycoprotein that binds to specific receptors on hematopoietic cells, promoting their proliferation, differentiation, and functional activation. It specifically enhances neutrophil production and function, including improved phagocytic ability and metabolic priming.
Approved indications
Common side effects
- Thrombocytopenia
- Nausea
- Pyrexia
- Chest pain
- Pain
- Fatigue
- Back pain
- Arthralgia
- Bone pain
- Pain in extremity
- Dizziness
- Cough
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (PHASE1)
- Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FILGRASTIM CI brief — competitive landscape report
- FILGRASTIM updates RSS · CI watch RSS
Frequently asked questions about FILGRASTIM
What is FILGRASTIM?
How does FILGRASTIM work?
What drug class is FILGRASTIM in?
When was FILGRASTIM approved?
What development phase is FILGRASTIM in?
What are the side effects of FILGRASTIM?
What does FILGRASTIM target?
Related
- Drug class: All Leukocyte Growth Factor [EPC] drugs
- Target: All drugs targeting Specific cell surface receptors on hematopoietic cells
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing